Eli Lilly SDE onboarding and first 90 days tips 2026

Your survival depends on treating 21 CFR Part 11 and GAMP 5 not as documentation hurdles but as architectural constraints that dictate your system design decisions from day one. Unlike consumer tech companies where A/B testing drives decisions, Eli Lilly operates under the shadow of the FDA, meaning

TL;DR

During a debrief for a Level 5 SDE role in the Oncology Data Platform team in late 2024, the hiring committee rejected a candidate with strong distributed systems experience because they could not articulate how they would handle audit trails for data mutations. The hiring manager noted, "They talked about eventual consistency; we need immediate, immutable audit logs for every state change." This is not a suggestion; it is a regulatory requirement.

The candidates who treat Eli Lilly like a standard tech firm fail their probation review before day 45 because they ignore the regulatory weight of GxP compliance in every line of code.

You are not joining a startup where moving fast and breaking things is a virtue; you are entering an environment where breaking a build can delay a clinical trial or trigger an FDA audit finding. In the Q4 2025 engineering all-hands for the Diabetes Care digital health unit, the VP of Engineering explicitly stated that velocity metrics are secondary to data integrity validation.

A Senior SDE hired from a FAANG background spent their first month optimizing CI/CD pipeline speed, only to be pulled into a corrective action plan when their automated deployment skipped a mandatory electronic signature gate required by 21 CFR Part 11. The problem isn't your coding speed — it's your failure to recognize that at Eli Lilly, compliance is the product, and software is merely the vehicle. This article dissects the specific cultural and technical friction points new Software Development Engineers face in Indianapolis and remote hubs, offering a ruthless assessment of what leads to retention versus termination.

What specific compliance frameworks must an Eli Lilly SDE master in the first month?

The first counter-intuitive truth is that your ability to write clean code matters less than your ability to document why that code exists in a way an auditor can verify three years later. In the Loxo Oncology integration project, engineers spent 40% of their sprint capacity writing validation protocols rather than feature code. If you view this as bureaucracy, you will fail.

If you view it as the definition of done, you will thrive. The second insight is that "technical debt" at Lilly is often a regulatory risk, not just a maintenance issue. A legacy module in the supply chain tracking system was kept running on an older Java version not because of inertia, but because re-validating the new version would require a six-month clinical impact assessment.

You must internalize the distinction between GxP and non-GxP environments immediately. Not every repository at Eli Lilly is subject to the same rigor; the internal HR portal operates differently than the clinical trial randomization engine. However, new hires often assume everything is low-risk and apply consumer-grade shortcuts to GxP systems. In a Q2 2025 incident, a junior engineer introduced a third-party logging library into a manufacturing execution system without vetting its data retention policies, resulting in a potential data privacy breach under GDPR and HIPAA.

The remediation cost the team three weeks of sprint time. Do not be the engineer who introduces unvetted dependencies. Your first month should be spent mapping the regulatory boundary of your specific product area. Ask your manager explicitly: "Is this system GxP critical?" If the answer is yes, your design documents must include a risk assessment section before you write a single unit test.

How does the 90-day ramp-up timeline differ for SDEs in pharma versus big tech?

The 90-day timeline at Eli Lilly is inverted compared to Silicon Valley, prioritizing domain knowledge and regulatory literacy over immediate code contribution for the first 45 days. In a typical FAANG onboarding, you are expected to push code to production within your first week; at Lilly, pushing code without understanding the clinical context is considered negligent.

During the 2023 onboarding cycle for the Alaunos health platform, the engineering lead mandated a "shadow phase" where new SDEs attended clinical operations meetings before accessing the codebase. One engineer resisted, arguing it was a waste of billable hours, and was subsequently managed out of the team by day 60 for repeatedly missing edge cases related to patient consent workflows. The problem isn't your lack of technical skill — it's your impatience with domain complexity.

The second counter-intuitive truth is that asking "business questions" is more valued than asking "architecture questions" in your first month. In a Google Cloud debrief, a candidate is praised for diving deep into Kubernetes configurations. At Eli Lilly, a candidate is praised for asking how a specific data field impacts the FDA submission timeline.

The organizational psychology principle at play here is "contextual safety." Pharma engineers operate in a high-stakes environment where errors have physical consequences. Your peers need to trust that you understand the stakes before they trust you with the codebase. In the Q3 2024 hiring cycle for the Indianapolis headquarters, the average time-to-first-meaningful-commit for new SDEs was 21 days, nearly double the industry average. This delay is intentional.

You will likely feel underutilized during weeks two through six. Resist the urge to filler tasks. Instead, use this time to build a mental model of the drug development lifecycle. Learn the difference between Phase 1, 2, and 3 trial data requirements.

Understand why a manufacturing batch record cannot be altered once closed. In a conversation with a Principal Engineer leading the antibody discovery platform, she revealed that the most successful new hires were those who spent their first month reading protocol documents rather than optimizing SQL queries. "We can teach you our internal frameworks in a week," she said. "We cannot teach you the gravity of a failed clinical trial in a week." Your goal for day 90 is not to have shipped the most features; it is to have shipped zero defects in a regulated environment. If you have shipped ten features but triggered one audit finding, you have failed.

📖 Related: Eli Lilly data scientist SQL and coding interview 2026

What are the unspoken cultural expectations for collaboration between SDEs and scientists?

Success at Eli Lilly requires translating between the deterministic logic of software engineering and the probabilistic nature of biological science, a skill gap that destroys many promising hires. Scientists at Lilly think in terms of statistical significance, p-values, and biological variability; engineers think in terms of boolean logic, latency, and throughput. This cognitive mismatch creates friction.

In a 2024 project involving the automation of high-throughput screening data ingestion, an SDE team built a pipeline that rejected "outlier" data points to optimize storage efficiency. The scientists were furious because those outliers represented potential breakthrough compounds. The engineer had optimized for clean data; the scientist needed the noise. The problem isn't the code quality — it's the failure to respect the scientific method as a product requirement.

The third counter-intuitive truth is that you must sometimes write "inefficient" code to accommodate scientific workflows. A rigid schema that forces data normalization might break a researcher's exploratory analysis tool. During a design review for the genomics data lake, a Staff Engineer pushed back on a proposed normalization strategy, arguing, "Biologists need to see the raw reads, even if it doubles our storage costs." The room went silent, then the VP nodded.

At Lilly, enabling scientific discovery often trumps infrastructure elegance. If you argue for purity of architecture over scientific flexibility, you will lose influence. You are a service provider to the science, not the other way around.

Collaboration also means accepting that requirements will change based on clinical data, not market feedback. In consumer tech, pivots happen based on user engagement metrics. At Lilly, pivots happen because a drug failed safety trials or the FDA requested additional data points. This can feel chaotic to an engineer used to stable roadmaps.

In the Q1 2025 planning session for a clinical supply chain tool, the roadmap was completely rewritten overnight after a regulatory update regarding cold-chain monitoring. The engineers who complained about "scope creep" were labeled as resistant to change. The engineers who immediately prototyped the new temperature logging requirements were fast-tracked for promotion. Your ability to pivot without cynicism is a key performance indicator. Do not say, "This wasn't in the spec." Say, "Given the new regulatory constraint, here is how we adapt the architecture." This shift in mindset separates the tenured engineers from the turnover statistics.

How should an SDE navigate internal tooling and legacy systems specific to Lilly?

Navigating Eli Lilly's technology landscape requires a forensic approach to legacy systems, where 20-year-old mainframes often hold the source of truth for critical manufacturing data. Many new SDEs arrive expecting a greenfield cloud-native environment, only to find themselves integrating modern microservices with AS/400 systems running RPG code. In the 2023 modernization of the global ERP system, a team of SDEs attempted to wrap a legacy inventory module with a REST API without understanding the batch-processing windows of the underlying system.

They caused a race condition that halted production scheduling for a key insulin facility for four hours. The post-mortem revealed that no one had read the 1998 operational manual for the legacy system. The problem isn't the legacy tech — it's the arrogance of assuming modern patterns apply universally.

You must adopt a "strangler fig" pattern mindset, but move at a glacial pace compared to startup standards. Refactoring at Lilly is not just a technical exercise; it is a validation exercise. Every time you replace a legacy function, you must prove that the new function produces bitwise identical results for regulated outputs, or scientifically justifiable variations for research outputs.

In the Diabetes Care unit, a migration from an on-prem Oracle database to AWS Aurora took 18 months, with six months dedicated solely to parallel run validation. A junior engineer suggested skipping the parallel run for "low risk" tables to accelerate the timeline. That suggestion was immediately escalated to the Quality Assurance head. Never suggest skipping validation steps to save time.

Work through a structured preparation system (the PM Interview Playbook covers system design trade-offs in regulated industries with real debrief examples) to understand how to document these migrations. The documentation you produce is as important as the code. You need to create traceability matrices linking requirements to code to test cases. If an auditor asks why a specific line of code exists, you must be able to point to a specific requirement ID.

In a recent interview loop for a backend role, the candidate was asked to design a logging system. The candidate focused on latency and throughput. The interviewer stopped them and asked, "How do you ensure this log cannot be tampered with by an admin?" The candidate failed because they treated it as a performance problem, not a security and compliance problem. Your mental model of "internal tooling" must include "auditability" as a primary non-functional requirement.

📖 Related: Eli Lilly data scientist interview questions 2026

Preparation Checklist

Map the Regulatory Boundary: Before writing code, identify if your service falls under GxP. If yes, download the relevant Standard Operating Procedures (SOPs) for software validation and read them cover to cover. Do not rely on verbal guidance; the written SOP is the law.
Audit Trail Architecture Design: Design your data models with immutable audit logs as a first-class citizen, not an afterthought. Ensure every create, update, and delete operation captures the user ID, timestamp, and reason for change in a separate, write-once table.
Stakeholder Shadowing Schedule: Schedule thirty-minute coffee chats with two scientists or clinical operations staff in your product area within your first two weeks. Ask them: "What is the one data error that keeps you up at night?" Use their answer to prioritize your testing strategy.
Legacy System Forensics: Identify the oldest system your team interacts with. Find the original documentation (even if it is a PDF from 2005) and read the section on "Known Issues" and "Batch Windows." This knowledge prevents catastrophic integration errors.
Validation Protocol Drafting: Practice writing a Validation Protocol document for a hypothetical feature. Define the "Acceptance Criteria" in a way that is binary and testable by a Quality Assurance auditor who knows nothing about code.
Dependency Vetting Workflow: Establish a personal checklist for introducing third-party libraries. Verify license compatibility, check for known security vulnerabilities (CVEs), and confirm data residency compliance before adding a single line to pom.xml or package.json.
Simulation of Audit Questions: Prepare answers for the question: "Show me the evidence that this code does exactly what the requirement says." Have a folder ready with traceability links, test results, and code reviews for your first small commit.

Mistakes to Avoid

Mistake 1: Prioritizing Velocity Over Validation

BAD: An SDE pushes a hotfix to the clinical trial randomization service on a Friday afternoon to "unblock the scientists," bypassing the full regression suite to save time.

GOOD: The SDE identifies the critical bug, documents the risk, initiates the emergency change control board (CCB) process, runs the targeted validation protocol, and deploys only after QA sign-off, even if it takes until Monday.

Judgment: Speed without validation is negligence. At Lilly, a delayed trial is bad; a compromised trial is fatal to the company's reputation and stock price.

Mistake 2: Treating Scientists as "Customers" Instead of Partners

BAD: An engineer builds a dashboard based strictly on the Jira ticket requirements, ignoring the scientist's verbal comment that "these outliers look weird but might be important."

GOOD: The engineer pauses development, meets with the scientist to analyze the outliers, discovers they represent a new biological marker, and adjusts the data pipeline to preserve and highlight them.

Judgment: Requirements documents in pharma are often incomplete because the science is evolving. Your job is to discover the real need, not just ticket-check.

Mistake 3: Assuming Cloud-Native Patterns Apply Everywhere

BAD: An SDE proposes replacing a stable, validated mainframe batch job with a serverless Lambda function to "modernize the stack" without calculating the re-validation cost.

GOOD: The SDE acknowledges the technical debt but quantifies the regulatory cost of re-validation ($250,000 and 6 months) and proposes keeping the legacy system until a larger business case justifies the migration.

Judgment: Technical purity is expensive. In pharma, the cost of change includes the cost of proving the change didn't break compliance.

FAQ

Is coding proficiency less important than regulatory knowledge at Eli Lilly?

Coding proficiency is the entry fee; regulatory knowledge is the promotion criterion. You will not be hired without strong algorithms and system design skills, as the bar for L4/L5 roles matches FAANG standards. However, once hired, your career trajectory depends entirely on your ability to apply those skills within GxP constraints. A brilliant coder who ignores compliance becomes a liability; a competent coder who masters validation becomes a leader. The judgment is binary: you must be excellent at both, but compliance failures are terminal events for your tenure.

Can I transition from a consumer tech background to Eli Lilly without prior pharma experience?

Yes, but you must aggressively self-educate on FDA regulations before day one. Hiring managers expect a steep learning curve, but they do not tolerate repeated basic errors regarding data integrity. Candidates who complete certifications in GxP or 21 CFR Part 11 prior to starting demonstrate the "contextual safety" mindset required.

Do not wait for training; the onboarding curriculum is broad, not deep. Your specific product area's nuances are your responsibility to learn immediately. The market compensates this transition with stable base salaries ranging from $145,000 to $195,000 depending on level, plus significant long-term incentives tied to drug pipeline success.

How often do SDEs at Eli Lilly interact directly with FDA auditors?

Direct interaction is rare for individual contributors but indirect exposure is daily. You will not sit in a room with an FDA inspector unless you are a Director or VP, but your code, logs, and documentation will be scrutinized by them during audits. Every commit you make is potentially evidence in a regulatory filing.

Treat every code review as if an auditor will read it in two years. This mindset shift is the single biggest differentiator between successful hires and those who struggle. If you cannot write code that explains itself to a non-technical regulator, you are not ready for this environment.

Ready to build a real interview prep system?

Get the full PM Interview Prep System →

The book is also available on Amazon Kindle.